62 related articles for article (PubMed ID: 36672182)
1. [Preparation of a novel tri-specific T cell engager targeting CD19 antigen and its anti-leukemia effect exploration].
Chen ML; Peng N; Liu XY; Zhang T; Xu YX; Tian Z; Xing HY; Tang KJ; Rao Q; Wang JX; Wang M
Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):217-223. PubMed ID: 33910307
[No Abstract] [Full Text] [Related]
2. Getting CD19 Into Shape: Expression of Natively Folded "Difficult-to- Express" CD19 for Staining and Stimulation of CAR-T Cells.
Lobner E; Wachernig A; Gudipati V; Mayrhofer P; Salzer B; Lehner M; Huppa JB; Kunert R
Front Bioeng Biotechnol; 2020; 8():49. PubMed ID: 32117929
[TBL] [Abstract][Full Text] [Related]
3. Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens.
Walsh ZH; Shah P; Kothapalli N; Shah SB; Nikolenyi G; Brodtman DZ; Leuzzi G; Rogava M; Mu M; Ho P; Abuzaid S; Vasan N; AlQuraishi M; Milner JD; Ciccia A; Melms JC; Izar B
Nat Biotechnol; 2024 May; ():. PubMed ID: 38783148
[TBL] [Abstract][Full Text] [Related]
4. CD19-directed T cell-engaging antibodies for the treatment of autoimmune disease.
Michaelson JS; Baeuerle PA
J Exp Med; 2024 May; 221(5):. PubMed ID: 38587494
[TBL] [Abstract][Full Text] [Related]
5. Signatures of dysfunctional CAR T cells.
Maus MV
Blood; 2023 Jun; 141(26):3127-3129. PubMed ID: 37383003
[No Abstract] [Full Text] [Related]
6. Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying a bispecific T cell engager against hepatocellular carcinoma.
Yuan X; Lu Y; Yang Y; Tian W; Fan D; Liu R; Lei X; Xia Y; Yang L; Yan S; Xiong D
Oncoimmunology; 2023; 12(1):2219544. PubMed ID: 37274296
[TBL] [Abstract][Full Text] [Related]
7. Plant-derived natural products and combination therapy in liver cancer.
Wang Y; Li J; Xia L
Front Oncol; 2023; 13():1116532. PubMed ID: 36865794
[TBL] [Abstract][Full Text] [Related]
8. Review of T cell proliferation regulatory factors in treatment and prognostic prediction for solid tumors.
Li J; Ma S; Pei H; Jiang J; Zou Q; Lv Z
Heliyon; 2023 Nov; 9(11):e21329. PubMed ID: 37954355
[TBL] [Abstract][Full Text] [Related]
9. CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).
Tasian SK; Gardner RA
Ther Adv Hematol; 2015 Oct; 6(5):228-41. PubMed ID: 26425336
[TBL] [Abstract][Full Text] [Related]
10. [CD19 antigen loss after treatment of Bispecific T-cell Engager and effective response to salvage bispecific CAR-T therapy in B cell acute lymphoblastic leukemia: a case report and literature review].
Fu XH; Wang Y; Wang HJ; Wei SN; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang JX; Wang M
Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):282-286. PubMed ID: 32447930
[No Abstract] [Full Text] [Related]
11. A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2
Hombach AA; Ambrose C; Lobb R; Rennert P; Abken H
Cells; 2023 Jan; 12(2):. PubMed ID: 36672182
[TBL] [Abstract][Full Text] [Related]
12. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition.
Yuti P; Wutti-In Y; Sawasdee N; Kongkhla K; Phanthaphol N; Choomee K; Chieochansin T; Panya A; Junking M; Yenchitsomanus PT; Sujjitjoon J
Int Immunopharmacol; 2022 Dec; 113(Pt B):109442. PubMed ID: 36435066
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
Ambrose C; Su L; Wu L; Dufort FJ; Sanford T; Birt A; Hackel BJ; Hombach A; Abken H; Lobb RR; Rennert PD
PLoS One; 2021; 16(3):e0247701. PubMed ID: 33735268
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study.
Thakur A; Scholler J; Schalk DL; June CH; Lum LG
J Cancer Res Clin Oncol; 2020 Aug; 146(8):2007-2016. PubMed ID: 32449004
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
